Clinical trials: High-Risk Cancer
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma
RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Giving vaccine therapy after an autologous stem cell transplant may kill any cancer cells that remain after transplant.
- Conditions
- Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Small Intestine Cancer
- Trial name
- NCT00569309
- Testing
- Streptococcus pneumoniae, laboratory correlative studies, quality-of-life assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Ovarian Cancer
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
The objective of this study was to evaluate the efficacy and safety of alpelisib in combination with olaparib compared with single-agent cytotoxic chemotherapy in participants with platinum-resistant or platinum-refractory…
- Trial name
- NCT04729387
- Testing
- Alpelisib, Olaparib, Paclitaxel
- Where
- 93 sites in United States, Argentina and 24 more
- Volunteers
- 358 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
This is a single-center, single arm, open-label phase II study evaluating the safety, anti-tumor effect, and immunogenicity of neoadjuvant Dupixent given prior to radical prostatectomy.
- Trial name
- NCT03886493
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NSCLC, Gastric Cancer
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
This is a Phase 1b study evaluating a combination of PEGPH20 and pembrolizumab in hyaluronan-high (HA-high) participants with relapsed/refractory non-small cell lung cancer (NSCLC) and HA-high participants with…
- Trial name
- NCT02563548
- Testing
- PEGPH20, Pembrolizumab
- Where
- 28 sites in United States
- Volunteers
- 56 people
- Sponsor
- Halozyme Therapeutics
Ganglioneuroblastoma, Stage 1 Neuroblastoma
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
This pilot clinical trial studies busulfan, melphalan, and stem cell transplant after chemotherapy in treating patients with newly diagnosed neuroblastoma that is likely to come back or spread.
- Conditions
- Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma
- Trial name
- NCT01798004
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin
- Where
- 123 sites in United States, Australia and 2 more
- Volunteers
- 150 people
- Sponsor
- Children's Oncology Group
Prostate Neoplasms
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
The purpose of this study is to determine if newly diagnosed (within previous 3 months) participants with metastatic (spread of cancer cells from one part of the body to another ) hormone-naive prostate cancer (mHNPC) who have…
- Trial name
- NCT01715285
- Testing
- Abiraterone acetate, Prednisone, Androgen deprivation therapy (ADT)
- Where
- 208 sites in Argentina, Australia and 31 more
- Volunteers
- 1,209 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
High Dose Carfilzomib for Newly Diagnosed Myeloma
The purpose of this study is to test whether giving high doses of carfilzomib along with the other drugs (lenalidomide and dexamethasone) is safe and which dose is best tolerated by patients.
- Trial name
- NCT02937571
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Osteosarcoma
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
The purpose of this Phase II study will assess the effectiveness of the combination of oral cyclophosphamide and sirolimus in sarcoma patients with relapsed or widespread disease who cannot be cured by surgery, radiation or…
- Trial name
- OCR (NCT00743509)
- Testing
- Cyclophosphamide and Sirolimus
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Michigan Rogel Cancer Center
Glioblastoma
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma.
- Trial name
- INTELLANCE-2 (NCT02343406)
- Testing
- Depatuxizumab mafodotin, Temozolomide, Lomustine
- Where
- 102 sites in United States, Australia and 19 more
- Volunteers
- 266 people
- Sponsor
- AbbVie
Uterine Cancer
A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus
The main purpose of this study us to determine the best treatment for patients with endometrial cancer who are at an elevated risk for recurrence.
- Trial name
- NCT00584909
- Testing
- Paclitaxel and carboplatin combination
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Alabama at Birmingham
Lymphoma
Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003631
- Testing
- filgrastim, carboplatin, carmustine
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma
PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer
This clinical trial studies positron emission tomography (PET)/computed tomography (CT) and lymph node mapping in finding lymph node metastasis in patients with endometrial cancer that is at high risk of spreading.
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma, Grade 3 Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT01737619
- Testing
- Computed Tomography, Indocyanine Green Solution, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 101 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, Precancerous Condition
Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer
RATIONALE: Calcitriol may prevent lung cancer in patients with metaplasia or dysplasia of the lungs. PURPOSE: This clinical trial is studying the side effects and best dose of calcitriol in preventing lung cancer in current…
- Conditions
- Lung Cancer, Precancerous Condition, Tobacco Use Disorder
- Trial name
- NCT00690924
- Testing
- calcitriol, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Primary Myelofibrosis, Post-Polycythemia Vera
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy (BAT) in subjects with DIPSS (Dynamic International Prognostic Scoring System)-intermediate…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera, Myelofibrosis
- Trial name
- FREEDOM2 (NCT03952039)
- Testing
- FEDRATINIB, Best Available Therapy (BAT)
- Where
- 107 sites in Australia, Austria and 14 more
- Volunteers
- 202 people
- Sponsor
- Celgene
High Risk Smoldering Multiple Myeloma
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
The purpose of this research study is to test whether the drug ibrutinib (trademark name: IMBRUVICA®) is effective at preventing the development of multiple myeloma in people who currently have smoldering myeloma.
- Trial name
- NCT02943473
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostate Cancer
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00430183
- Testing
- docetaxel, LHRH agonist, surgery
- Where
- 226 sites in United States, Canada
- Volunteers
- 788 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia
Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia
This randomized clinical trial studies liposomal cytarabine-daunorubicin CPX-351 in treating patients with untreated myelodysplastic syndrome or acute myeloid leukemia.
- Conditions
- Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
- Trial name
- NCT01804101
- Testing
- Laboratory Biomarker Analysis, Liposomal Cytarabine-Daunorubicin CPX-351
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Fred Hutchinson Cancer Center
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
High-Dose Stereotactic Radiation for Prostate Cancer
This clinical trial studies high-dose stereotactic body radiation therapy (SBRT) in treating patients with low-, intermediate-, or high-risk localized prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01664130
- Testing
- stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Case Comprehensive Cancer Center
Invasive Fungal Infections, Hematologic Malignancies
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
The objective of this study is to compare the safety and efficacy of ABLC versus oral Posaconazole in the prevention of invasive fungal infections in high risk patients with hematologic malignancies or hematopoietic stem cell…
- Trial name
- NCT00750737
- Testing
- Posaconazole, ABLC
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase I study to establish safety and feasibility of intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT03585764
- Testing
- MOv19-BBz CAR T cells, Alpha Folate Receptor expression test
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Pennsylvania
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.